Glenn S Tillotson (Glenn Tillotson)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 24

Top Topics

Urinary Tract Infection

Clostridium Difficile

Ejection Fraction

Top Venues

Open forum infectious diseases

Therapeutic advances in gastroenterology

BMC infectious diseases

The Journal of antimicrobial chemotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Glenn S Tillotson
Comment on: Community-acquired pneumonia: a US perspective on the guideline gap. The Journal of antimicrobial chemotherapy (2024)
Herbert L DuPont, Andrew W DuPont, Glenn S Tillotson
Microbiota restoration therapies for recurrent Clostridioides difficile infection reach an important new milestone. Therapeutic advances in gastroenterology 17 (2024)
Glenn S Tillotson
Comment on: Community-acquired pneumonia: a US perspective on the guideline gap. The Journal of antimicrobial chemotherapy (2024)
Herbert L DuPont, Andrew W DuPont, Glenn S Tillotson
Microbiota restoration therapies for recurrent Clostridioides difficile infection reach an important new milestone. Therapeutic advances in gastroenterology 17 (2024)
Antoine Boustany, Paul Feuerstadt, Glenn S Tillotson
The 3 Ds: Depression, Dysbiosis, and Clostridiodes difficile. Advances in therapy (2024)
Lea M Monday, Glenn S Tillotson, Teena Chopra
Microbiota-Based Live Biotherapeutic Products for Clostridioides Difficile Infection- The Devil is in the Details. Infection and drug resistance 17 (2024)
Lea M Monday, Glenn S Tillotson, Teena Chopra
Microbiota-Based Live Biotherapeutic Products for Clostridioides Difficile Infection- The Devil is in the Details. Infection and drug resistance 17 (2024)
Glenn S Tillotson
Comment on: Community-acquired pneumonia: a US perspective on the guideline gap. The Journal of antimicrobial chemotherapy 79 (8) (2024)
Paul Feuerstadt, Nicolette Theriault, Glenn S Tillotson
The burden of CDI in the United States: a multifactorial challenge. BMC infectious diseases 23 (1) (2023)
Paul Feuerstadt, Caterina Oneto, Glenn S Tillotson, Nicholas W Van Hise
Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection. Patient preference and adherence 17 (2023)
Paul Feuerstadt, Nicolette Theriault, Glenn S Tillotson
The burden of CDI in the United States: a multifactorial challenge. BMC infectious diseases 23 (1) (2023)
Glenn S Tillotson, Gayatri Vedantam, Jae Hyun Shin, Cirle A Warren
The Importance of a Broad Consortium of Bacteria for a Healthy Gastrointestinal tract: A Narrative Review of the Live Biotherapeutic Product REBYOTA. Open forum infectious diseases 10 (11) (2023)
Paul Feuerstadt, Nicolette Theriault, Glenn S Tillotson
The burden of CDI in the United States: a multifactorial challenge. BMC infectious diseases 23 (1) (2023)
Paul Feuerstadt, Caterina Oneto, Glenn S Tillotson, Nicholas W Van Hise
Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection. Patient preference and adherence 17 (2023)
Teena Chopra, Phil Hylemon, Glenn S Tillotson
Role of the microbiome in essential metabolism in the human gut and its implications for Clostridioides difficile infection. Open forum infectious diseases 10 (9) (2023)
Glenn S Tillotson, Laurie Archbald-Pannone, Stuart Johnson, Samson Ng, Masakazu Ando, Adam Harvey, Lindy Bancke, Paul Feuerstadt
Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities. Open forum infectious diseases 10 (1) (2022)
Sahil Khanna, James Lett, Cheri Lattimer, Glenn S Tillotson
Transitions of care in Clostridioides difficile infection: a need of the hour. Therapeutic advances in gastroenterology 15 (2022)
Glenn S Tillotson, Laurie Archbald-Pannone, Stuart Johnson, Samson Ng, Masakazu Ando, Adam Harvey, Lindy Bancke, Paul Feuerstadt
Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities. Open forum infectious diseases 10 (1) (2022)
Glenn S Tillotson, Laurie Archbald-Pannone, Stuart Johnson, Samson Ng, Masakazu Ando, Adam Harvey, Lindy Bancke, Paul Feuerstadt
Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities. Open forum infectious diseases 10 (1) (2022)
Simon Portsmouth, Almasa Bass, Roger Echols, Glenn S Tillotson
Heterogeneity of Recent Phase 3 Complicated Urinary Tract Infection Clinical Trials. Open forum infectious diseases 8 (3) (2021)
Bin Cai, Glenn S Tillotson, Darrin Benjumea, Patrick Callahan, Roger Echols
The Burden of Bloodstream Infections due to Stenotrophomonas Maltophilia in the United States: A Large, Retrospective Database Study. Open forum infectious diseases 7 (5) (2020)
Teena Chopra, Avnish Sandhu, Nicolette Theriault, Joni Meehan, Glenn S Tillotson
Omadacycline: a therapeutic review of use in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Future microbiology 15 (2020)
Glenn S Tillotson, Thomas Lodise, Peter Classi, Donna Mildvan, James A McKinnell
Antibiotic Treatment Failure and Associated Outcomes Among Adult Patients With Community-Acquired Pneumonia in the Outpatient Setting: A Real-world US Insurance Claims Database Study. Open forum infectious diseases 7 (3) (2020)
Ellie J C Goldstein, Glenn S Tillotson, Mark Redell
Antimicrobial Management of Respiratory Infections in Severe Acute Respiratory Syndrome Coronavirus 2 Patients: Clinical and Antimicrobial Stewardship Programs Conundrums. Open forum infectious diseases 7 (11) (2020)